WeVote
Log In

Bill

Bill

HB 5262

AN ACT CONCERNING CERTAIN ELECTRONIC NOTICE REQUIREMENTS FOR PROPERTY AND CASUALTY INSURERS, THE STATE INSURANCE AND RISK MANAGEMENT BOARD'S RESERVE FUNDING, REVIEW OF THE MOTOR VEHICLE GLASS REPAIR NATIONAL MODEL, AND THE OFFICE OF HEALTH STRATEGY'S REPORTING REQUIREMENTS RELATED TO PRESCRIPTION DRUG FORMULARIES.

2026 Regular Session

Connecticut updates insurance regulations on electronic notices, state reserve funding, vehicle glass repair standards, and prescription drug transparency reporting requirements.

PUBLIC HEARING 0224
0
WeVote Research Nonpartisan
Bill Summary · HB 5262

Legislative bill overview

HB 5262 is a Connecticut omnibus bill addressing four separate insurance and healthcare policy matters: updating electronic notice requirements for property and casualty insurers, adjusting the State Insurance and Risk Management Board's reserve funding mechanisms, reviewing national standards for motor vehicle glass repair practices, and establishing new reporting requirements for the Office of Health Strategy regarding prescription drug formularies.

Why is this important

These changes affect how insurance companies communicate with policyholders, how the state manages its insurance reserves, standards for vehicle repair costs, and transparency around prescription drug coverage. Together, they influence insurance affordability, consumer protection, healthcare access, and state fiscal management.

Potential points of contention

  • Electronic notice modernization: Insurers may argue compliance costs are high, while consumer advocates may worry about adequate notification reaching all policyholders
  • Reserve funding adjustments: Changes could affect the state's financial flexibility and insurance market stability; disagreement likely on whether reserves are adequate
  • Motor vehicle glass repair standards: Independent repair shops may oppose national model adoption if it favors larger insurers or specific vendors, while insurers may support standardization to control costs
  • Formulary reporting requirements: Pharmaceutical manufacturers and insurers may resist increased transparency requirements, while consumer groups will likely support greater visibility into drug coverage decisions

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.